Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 470

Articles by Marisa Woutersen

GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation
Pharma
GSK lands 36-country injunction in Pfizer-BioNTech vaccine litigation
Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.   12 November 2026
‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
Pharma
‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.   12 November 2026
How in-house teams can get more value from external counsel
In-house counsel
How in-house teams can get more value from external counsel
From deciding what to outsource to managing legal fees and foreign counsel relationships, panellists at LSPN Fall, from Addition Therapeutics, Arcus Biosciences and the Law Office of Athena Zhou, shared practical advice for making IP budgets go further.   9 November 2026
Regulation & Industry
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.   5 November 2026
In-house counsel
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
AI agents are no longer just helping patent lawyers with their workload. Some are now doing the work themselves. In-house counsel from Insitro, Illumina, 10x Genomics and Invenra discuss how much can be handed over and whether humans could be replaced.   4 November 2026
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.   3 November 2026
Regulation & Industry
UK unveils £1bn sector investment push after recent setbacks
With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.   30 October 2026
MedTech
Meril turns the tables on Edwards with European patent revocation
Despite earlier wins at the UPC and EPO, a key heart valve patent has been revoked on appeal, with the latest ruling highlighting diverging approaches to patent validity in Europe and raising questions ahead of a separate UPC appeal.   29 October 2026
Careers
Latham lands pharma and tech expert in London
The US firm has added a top litigator with experience in pharmaceutical disputes, AI and technology, and complex cross-border litigation, who also made history as the youngest person appointed deputy master of the High Court’s Business and Property Division.   29 October 2026
Biotech
Regeneron and Amgen call a truce on two Eylea biosimilar patents
Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.   28 October 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.